2024.07.14 (일)

  • 구름많음동두천 25.5℃
  • 흐림강릉 21.8℃
  • 맑음서울 28.5℃
  • 구름많음대전 26.8℃
  • 대구 24.4℃
  • 울산 22.5℃
  • 구름많음광주 26.6℃
  • 흐림부산 24.3℃
  • 흐림고창 24.4℃
  • 제주 26.9℃
  • 맑음강화 26.4℃
  • 구름많음보은 25.1℃
  • 구름많음금산 26.6℃
  • 흐림강진군 24.0℃
  • 흐림경주시 23.6℃
  • 흐림거제 22.3℃
기상청 제공

경제

Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of Common Stock

[By NBC-1TV H. J Yook]Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the pricing of an underwritten public offering of 16,375,000 shares of its common stock. The gross proceeds to Synergy from this offering are expected to be $90,062,500, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Synergy. The offering is expected to close on or about April 16, 2013, subject to customary closing conditions. Synergy has also granted to the underwriter a 30-day option to purchase from it up to an additional 2,456,250 shares of its common stock.

Synergy intends to use the net proceeds from this offering to fund its research and development activities, including further clinical development of plecanatide and its other pipeline programs, and for working capital and other general corporate purposes, and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.

Credit Suisse, Citigroup and Canaccord Genuity are acting as book-running managers in this offering, and Cantor Fitzgerald is acting as a co-manager.

A registration statement relating to the shares described above was previously filed with and has become effective by rule of the Securities and Exchange Commission (SEC). A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and related prospectus, when available, may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by e-mail at newyork.prospectus@credit-suisse.com; or Citigroup, c/o Broadbridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (800) 831-9146, or by e-mail at batprospectus@citi.com; or Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone at (617) 371-3900.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.



배너

관련기사


배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너